+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07674654

Long-Term Safety Study Evaluating Intermittent Oral Elismetrep for Acute Migraine Treatment

Led by TriGemX Bio, Inc. · Updated on 2026-11-02

1000

Participants Needed

113

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.

CONDITIONS

Brief Title

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Research Team

A

Annemarie Vance

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here